newsfilter
← Latest News
Business Wire·

Gemini Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update

GEM103 updated safety information presented during AAO including no increased risk for CNV observed to date in ongoing ReGAtta Phase 2a study Expect to provide six-month update from GEM103 ReGAtta study by year-end Scheduled to meet with the FDA i